CFDA approved two new indications
-
Last Update: 2015-06-18
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, Bayer healthcare announced that CFDA has approved two new indications for the treatment of adult deep vein thrombosis (DVT), reducing the risk of DVT recurrence and pulmonary embolism after acute DVT; and adult patients with non valvular atrial fibrillation with one or more risk factors to reduce stroke and systemic embolism Risk So far, three indications including prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement have been approved in China, and it is also the only new oral anticoagulant approved for treatment and recurrence prevention of deep vein thrombosis in China According to the results of Einstein DVT study, the efficacy of rivaroxaban group is not inferior to that of LMWH plus warfarin group, and it does not increase the risk of massive hemorrhage Moreover, this new and effective alternative therapy, without the limitations of conventional monitoring, injection or diet control required by traditional treatment, provides great convenience for clinical application Bairituo is a new oral anticoagulant with the most extensive indications, which has been approved in more than 125 countries around the world.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
